CARLSBAD, Calif.--(BUSINESS WIRE)--Life Technologies Corporation (NASDAQ:LIFE), a provider of innovative life science solutions, today announced activities and product launches in concert with the International Society for Stem Cell Research (ISSCR) 8th Annual Meeting that highlight the company’s offerings of complete end-to-end solutions for stem cell research. Stem cell research has been shown to be a critical component of regenerative medicine; a basis for identifying drug targets and drug screening; and an important step in the development of therapies to treat a variety of diseases.
Life Technologies’ portfolio of workflow solutions addresses the entire stem cell continuum, including the isolation, expansion, differentiation and characterization of cells. The company’s innovative stem cell reagents offered under its Invitrogen brand coupled with its industry-leading instrument and workflow-based systems under its Applied Biosystems brand enable the acceleration of stem cell research breakthroughs.
Industry leaders at ISSCR will present research results using technologies that demonstrate the power of combining products across the Life Technologies stem cell offering under both the Invitrogen and Applied Biosystems brands. They include:
Research scientists at centers such as the Harvard Stem Cell Institute are utilizing a variety of technologies from the Life Technologies stem cell workflow. Dr. Kelvin Lam is one of many scientists presenting stem cell research at the ISSCR meeting this week. “Life Technologies is dedicated to understanding the complex nature of work that stem cell scientists engage in on a daily basis,” noted Dr. Lam, Director of High Throughput Screening at the Harvard Stem Cell Institute and Harvard University. “It is becoming important for technology providers to develop innovations to enhance the stem cell scientist’s quest to understand the biology of stem cells. We have a very positive partnership with the Life Technologies stem cell group through a collaborative project. We appreciate their dedication and insights in transforming the promise of stem cells into reality.”
“Over the past 5 years, our company has been investing in collaborations, partnerships and internal R&D programs to offer best-in-class stem cell products to our customers,” said Nicolas Barthelemy, President, Cell Systems Division at Life Technologies. “At ISSCR, with customer presentations that use technologies from both legacy brands, unified workshops and introduction of products that enhance the stem cell work flow, we are clearly demonstrating how Life Techologies continues to be the leader in advancing discoveries in the critical areas of stem cell research and regenerative medicine.”
As part of Life Technologies’ commitment to delivering innovative products to the stem cell industry, GIBCO® Cell Therapy Systems (CTS™), launched yesterday, will leverage a variety of the company’s offerings addressing the stem cell research continuum to support cell therapy applications and ultimately help cell therapy practitioners accelerate the transition from research to clinical applications.
Presentations at ISSCR
During the conference, several independent stem cell researchers will present commercial tutorials featuring data generated using products from both Invitrogen and Applied Biosystems, demonstrating the importance of Life Technologies’ innovations to the stem cell field.
About Life Technologies (www.lifetechnologies.com)
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com.
Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.